Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Hospitaler/afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Søg efter ekspertise, navn eller tilknytning
Cancer immune therapy for myeloid malignancies: present and future
Morten Orebo Holmström
, Hans Carl Hasselbalch
Center for Cancer Immune Therapy (CCIT), Department of Oncology, Copenhagen University Hospital , Herlev, Denmark.
13
Citationer (Scopus)
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'Cancer immune therapy for myeloid malignancies: present and future'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Keyphrases
Immune Response
100%
Treatment Strategy
100%
Myeloid Malignancies
100%
Therapeutic Treatment
100%
Immune Regulation
100%
Chronic Myeloproliferative Neoplasms
100%
Anticancer Immune Response
100%
Cancer Immune Therapy
100%
Immune Therapeutics
100%
Gene Expression
50%
Arginase-1 (Arg-1)
50%
Malignancy
50%
Clinical Trials
50%
Exon 9
50%
Treatment Options
50%
Immune System
50%
Vaccination
50%
Bone Marrow
50%
Epitope
50%
Tumor Antigen
50%
Regulatory Proteins
50%
Deregulation
50%
Acute Myeloid Leukemia
50%
Calreticulin
50%
Dysregulation
50%
Myelodysplastic Syndrome
50%
Hypomethylating Agents
50%
Therapeutic Vaccine
50%
Antitumor Immune Response
50%
Hematopoietic Stem Cells
50%
Preclinical Trials
50%
Treatment Potential
50%
Programmed Death-ligand 1 (PD-L1)
50%
Immune Cell Function
50%
Lymphoid Malignancies
50%
Cytokine Milieu
50%
Immune Parameters
50%
Concurrent Use
50%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Driver mutations
50%
Immune Checkpoint Inhibitors
50%
Vaccination Clinic
50%
Checkpoint Blocking Antibody
50%
Immune Checkpoint Blocking
50%
Medicine and Dentistry
Malignant Neoplasm
100%
Immune Response
100%
Immunotherapy
100%
Myeloid Malignancy
100%
Myeloproliferative Neoplasm
66%
Cytokine
33%
Disease
33%
Neoplasm
33%
Cancer
33%
Cell Function
33%
Immune System
33%
Immunocompetent Cell
33%
Epitope
33%
Lymphoma
33%
Acute Myeloid Leukemia
33%
Exon
33%
Myelodysplastic Syndrome
33%
Tumor Antigen
33%
Hematopoietic Stem Cell
33%
Cancer Immunization
33%
Regulator Protein
33%
Immunoregulation
33%
Calreticulin
33%
Immune Checkpoint Inhibitor
33%
Chimeric Antigen Receptor T-Cell
33%
Hypomethylating Agent
33%
Programmed Death 1 Ligand 1
33%
Arginase 1
33%
Blocking Antibody
33%